According to Oppenheimer, Curis CRIS coverage is initiated with an Outperform rating.
Oppenheimer said that it is initiating coverage of Curis Inc. with an Outperform rating and $6/share price target. “Our target price of $6/share is based on an NPV analysis of vismodegib in BCC and Gorlin syndrome, and we believe that a considerable upside remains outside of these indications and in the remainder of Curis's pipeline.”
Curis closed yesterday at $3.56.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in